Literature DB >> 8943481

SPARC is expressed in renal interstitial fibrosis and in renal vascular injury.

R H Pichler1, C Hugo, S J Shankland, M J Reed, J A Bassuk, T F Andoh, D M Lombardi, S M Schwartz, W M Bennett, C E Alpers, E H Sage, R J Johnson, W G Couser.   

Abstract

Tubulointerstitial inflammation and fibrosis are critical determinants for renal function and prognosis in a variety of human nephropathies. Yet, the pathophysiology of the injury remains obscure. We investigated the expression of SPARC (secreted protein acidic and rich in cysteine) by immunohistochemistry and in situ hybridization in experimental models characterized by tubulointerstitial fibrosis and matrix expansion in rats. SPARC is a secreted glycoprotein that has been demonstrated to affect cellular interaction with matrix proteins, modulate cell proliferation, bind to and/or inhibit growth factors such as PDGF and bFGF, and regulate angiogenesis. Interstitial expression of SPARC was most prominent in passive Heyman nephritis (PHN), chronic cyclosporine A (CsA) nephropathy, and the remnant kidney model and, to a lesser extent, in angiotensin II (Ang II)-infused animals. SPARC protein and mRNA were substantially increased at sites of tubulointerstitial fibrosis/matrix expansion. In the PHN model, SPARC protein was expressed by interstitial fibroblasts that also produced alpha-smooth muscle actin ("myofibroblasts") and correlated both temporally (r = 0.97) and spatially with sites of type I collagen deposition. Interstitial cell proliferation preceded the development of interstitial fibrosis, and maximal SPARC expression (d15) coincided with the initial decline in interstitial proliferation. In the Ang II-infusion model, which is characterized by arteriolopathy and tubulointerstitial injury, an increase in SPARC protein and mRNA was also seen in injured blood vessels. SPARC was shown to be expressed by vascular smooth muscle cells and also by cells in the adventitia of hypertrophied arteries. In summary, SPARC was transiently expressed by interstitial fibroblasts at sites of tubulointerstitial injury and fibrosis, and by smooth muscle cells and cells in the adventitia of injured arteries in the Ang II-model. In addition to its proposed role in extracellular matrix deposition. the antiproliferative properties of SPARC might contribute to the resolution of interstitial fibroblast proliferation in the PHN model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943481     DOI: 10.1038/ki.1996.520

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  24 in total

1.  Corticosteroid-regulated genes in rat kidney: mining time series array data.

Authors:  Richard R Almon; William Lai; Debra C DuBois; William J Jusko
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-06-28       Impact factor: 4.310

Review 2.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

3.  A fragment of SPARC reflecting increased collagen affinity shows pathological relevance in lung cancer - implications of a new collagen chaperone function of SPARC.

Authors:  S N Kehlet; T Manon-Jensen; S Sun; S Brix; D J Leeming; M A Karsdal; N Willumsen
Journal:  Cancer Biol Ther       Date:  2018-08-01       Impact factor: 4.742

4.  Substratum stiffness and latrunculin B regulate matrix gene and protein expression in human trabecular meshwork cells.

Authors:  Sara M Thomasy; Joshua A Wood; Philip H Kass; Christopher J Murphy; Paul Russell
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-23       Impact factor: 4.799

Review 5.  Matricellular proteins in the trabecular meshwork: review and update.

Authors:  Ayan Chatterjee; Guadalupe Villarreal; Douglas J Rhee
Journal:  J Ocul Pharmacol Ther       Date:  2014-06-05       Impact factor: 2.671

6.  Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension.

Authors:  Matthew J Socha; Marlina Manhiani; Neveen Said; John D Imig; Kouros Motamed
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 7.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

8.  SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery.

Authors:  Li-Fong Seet; Roseline Su; V A Barathi; Wing Sum Lee; Rebekah Poh; Yee Meng Heng; Ed Manser; Eranga N Vithana; Tin Aung; Matt Weaver; E Helene Sage; Tina T Wong
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

9.  Attenuation of fibrosis in vitro and in vivo with SPARC siRNA.

Authors:  Jiu-Cun Wang; Syeling Lai; Xinjian Guo; Xuefeng Zhang; Benoit de Crombrugghe; Sonali Sonnylal; Frank C Arnett; Xiaodong Zhou
Journal:  Arthritis Res Ther       Date:  2010-04-01       Impact factor: 5.156

10.  Secreted protein acidic and rich in cysteine (SPARC) in human skeletal muscle.

Authors:  Louise H Jørgensen; Stine J Petersson; Jeeva Sellathurai; Ditte C Andersen; Susanne Thayssen; Dorte J Sant; Charlotte H Jensen; Henrik D Schrøder
Journal:  J Histochem Cytochem       Date:  2008-09-15       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.